Form 4: Natera Executive Solomon Moshkevich Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold a portion of his holdings in common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 5, 2025, Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold shares of Natera's common stock.
- The sales were executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.
- A total of 6,000 shares were sold in multiple transactions at varying prices.
- The weighted average sale prices ranged from $142.0823 to $144.97 per share.
- Following the reported transactions, Moshkevich directly owns 143,768 shares of Natera's common stock.
Sentiment
Score: 5
Explanation: The document is a standard Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions under a pre-arranged plan.
Industry Context
Insider sales are a common occurrence, and the use of a 10b5-1 plan suggests the sales were pre-planned and not based on any specific non-public information.
Stakeholder Impact
- The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| 2024-11-26 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 2025-03-05 | Date of the stock sale transactions. |
| 2025-03-07 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.